Mirati Stock Analysis


USD 86.37  5.92  7.36%   

The current price rise of Mirati Therapeutics may encourage investors to take a closer look at the firm as it is trading at a share price of 86.37 on 672,200 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.49. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Mirati Therapeutics partners.
Additionally, see Stocks Correlation.
The Mirati Therapeutics stock analysis report makes it easy to digest most publicly released information about Mirati Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Mirati Stock analysis module also helps to analyze the Mirati Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Mirati Stock Analysis Notes

About 110.0% of the company shares are owned by institutional investors. The book value of Mirati Therapeutics was now reported as 20.0. The company has Price/Earnings To Growth (PEG) ratio of 0.03. Mirati Therapeutics recorded a loss per share of 11.96. The entity had not issued any dividends in recent years. The firm had 1:50 split on the 3rd of July 2013. Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. Mirati Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 413 people. To find out more about Mirati Therapeutics contact Charles Baum at 858 332-3410 or learn more at www.mirati.com.

Mirati Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Mirati Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Mirati Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Mirati Therapeutics is way too risky over 90 days horizon
Mirati Therapeutics appears to be risky and price may revert if volatility continues
Mirati Therapeutics is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 78.16 M. Net Loss for the year was (644.51 M) with profit before overhead, payroll, taxes, and interest of 72.09 M.
Mirati Therapeutics currently holds about 1.19 B in cash with (488.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.41.
Mirati Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from www.marketscreener.com: ORIC PHARMACEUTICALS, INC. Managements Discussion and Analysis of Financial Condition and Results of Operations. - Marketscreener.com

Mirati Therapeutics Upcoming and Recent Events

Earnings reports are used by Mirati Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mirati Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Mirati Largest EPS Surprises

Earnings surprises can significantly impact Mirati Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Mirati Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Mirati Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Mirati Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Mirati Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
7th of June 2022
Financial Statements and Exhibits. Other Events
6th of June 2022
Financial Statements and Exhibits. Other Events
26th of May 2022
Financial Statements and Exhibits. Other Events
16th of May 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
12th of May 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
28th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition

Mirati Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Mirati Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mirati Therapeutics backward and forwards among themselves. Mirati Therapeutics' institutional investor refers to the entity that pools money to purchase Mirati Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares4.5 M305.3 M
Blackrock IncCommon Shares2.4 M161.8 M
Fmr LlcCommon SharesM134.8 M
Franklin Resources IncCommon Shares1.5 M97.9 M
Artal Group SaCommon Shares1.1 M73.8 M
Assenagon Asset Management SaCommon Shares852 K57.2 M
Bank Of Nova ScotiaCommon Shares841 K56.5 M
Note, although Mirati Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Mirati Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 4.8 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mirati Therapeutics's market, we take the total number of its shares issued and multiply it by Mirati Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Mirati Profitablity

Mirati Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Mirati Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Mirati Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Mirati Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Mirati Therapeutics' profitability requires more research than a typical breakdown of Mirati Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(41.57) (44.85) 
Return on Average Assets(0.42) (0.45) 
Return on Average Equity(0.48) (0.51) 
Return on Invested Capital(0.58) (0.63) 
Return on Sales(8.02) (8.66) 

Management Efficiency

The entity has return on total asset (ROA) of (30.26) % which means that it has lost $30.26 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (57.52) %, meaning that it created substantial loss on money invested by shareholders. Mirati Therapeutics management efficiency ratios could be used to measure how well mirati therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -44.85 in 2022. Return on Average Assets is likely to drop to -0.45 in 2022. Mirati Therapeutics Total Assets are fairly stable at the moment as compared to the past year. Mirati Therapeutics reported Total Assets of 1.59 Billion in 2021. Current Assets is likely to rise to about 1.6 B in 2022, whereas Net Current Assets as percentage of Total Assets are likely to drop 78.05 in 2022.
Last ReportedProjected for 2022
Book Value per Share 26.93  29.05 
Enterprise Value over EBIT(13.00) (14.03) 
Enterprise Value over EBITDA(12.84) (13.85) 
Price to Book Value 5.44  6.82 
Tangible Assets Book Value per Share 30.62  33.04 
Enterprise Value7.4 BB
Tangible Asset Value1.6 B1.7 B

Technical Drivers

As of the 14th of August 2022, Mirati Therapeutics secures the Mean Deviation of 4.53, downside deviation of 7.28, and Risk Adjusted Performance of 0.1694. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mirati Therapeutics, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Mirati Therapeutics, which can be compared to its peers in the industry. Please verify Mirati Therapeutics variance and potential upside to decide if Mirati Therapeutics is priced some-what accurately, providing market reflects its recent price of 86.37 per share. Given that Mirati Therapeutics has jensen alpha of 0.8875, we recommend you to check Mirati Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.

Mirati Therapeutics Price Movement Analysis

The output start index for this execution was thirty-one with a total number of output elements of thirty. The Kaufman Adaptive Moving Average allows the user to define Mirati Therapeutics range across which they want the smoothing.

Mirati Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mirati Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mirati Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mirati Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Christensen Jamie over two months ago via Macroaxis 
Sale by Christensen Jamie of 624 shares of Mirati Therapeutics
Stelzer Laurie over two months ago via Macroaxis 
Acquisition by Stelzer Laurie of 91164 shares of Mirati Therapeutics subject to Rule 16b-3
Stelzer Laurie over two months ago via Macroaxis 
Mirati Therapeutics exotic insider transaction detected
Henry Fuchs over six months ago via Macroaxis 
Exercise or conversion by Henry Fuchs of 5000 shares of Mirati Therapeutics subject to Rule 16b-3
Julie Cherrington over six months ago via Macroaxis 
Sale by Julie Cherrington of 1475 shares of Mirati Therapeutics
Julie Cherrington over six months ago via Macroaxis 
Acquisition by Julie Cherrington of 3688 shares of Mirati Therapeutics subject to Rule 16b-3
Christensen Jamie over six months ago via Macroaxis 
Sale by Christensen Jamie of 1442 shares of Mirati Therapeutics
Christensen Jamie over six months ago via Macroaxis 
Acquisition by Christensen Jamie of 19149 shares of Mirati Therapeutics subject to Rule 16b-3
Christensen Jamie over six months ago via Macroaxis 
Sale by Christensen Jamie of tradable shares of Mirati Therapeutics
Charles Baum over six months ago via Macroaxis 
Exercise or conversion by Charles Baum of 47204 shares of Mirati Therapeutics subject to Rule 16b-3
Craig Johnson over six months ago via Macroaxis 
Sale by Craig Johnson of tradable shares of Mirati Therapeutics
Meek David D over six months ago via Macroaxis 
Acquisition by Meek David D of 150300 shares of Mirati Therapeutics subject to Rule 16b-3

Mirati Therapeutics Predictive Daily Indicators

Mirati Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mirati Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Mirati Therapeutics Forecast Models

Mirati Therapeutics time-series forecasting models is one of many Mirati Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mirati Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Mirati Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Mirati Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mirati shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Mirati Therapeutics. By using and applying Mirati Stock analysis, traders can create a robust methodology for identifying Mirati entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(8.00) (8.63) 
Gross Margin 0.90  0.89 
Profit Margin(8.07) (8.71) 
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. Mirati Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 413 people.

Current Mirati Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mirati analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mirati analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Mirati Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Mirati analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Mirati stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Mirati Therapeutics, talking to its executives and customers, or listening to Mirati conference calls.
Mirati Analyst Advice Details

Mirati Stock Analysis Indicators

Mirati Therapeutics stock analysis indicators help investors evaluate how Mirati Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Mirati Therapeutics shares will generate the highest return on investment. By understating and applying Mirati Therapeutics stock analysis, traders can identify Mirati Therapeutics position entry and exit signals to maximize returns.
Quick Ratio10.00
Fifty Two Week Low32.96
Shares Short Prior Month8.23M
Average Daily Volume Last 10 Day1.24M
Average Daily Volume In Three Month1.62M
Shares Percent Shares Out12.56%
Gross Margins100.00%
Short Percent Of Float15.67%
Forward Price Earnings-6.72
Float Shares41.52M
Fifty Two Week High195.99
Enterprise Value To Ebitda-5.76
Fifty Day Average65.21
Two Hundred Day Average95.91
Enterprise Value To Revenue46.86
Additionally, see Stocks Correlation. Note that the Mirati Therapeutics information on this page should be used as a complementary analysis to other Mirati Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Mirati Stock analysis

When running Mirati Therapeutics price analysis, check to measure Mirati Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mirati Therapeutics is operating at the current time. Most of Mirati Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mirati Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mirati Therapeutics' price. Additionally, you may evaluate how the addition of Mirati Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Valuation
Check real value of public entities based on technical and fundamental data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Mirati Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirati Therapeutics. If investors know Mirati will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirati Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.1 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Mirati Therapeutics is measured differently than its book value, which is the value of Mirati that is recorded on the company's balance sheet. Investors also form their own opinion of Mirati Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mirati Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirati Therapeutics' market value can be influenced by many factors that don't directly affect Mirati Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirati Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Mirati Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirati Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.